Mechanisms of antithrombotic drugs.
Thiagarajan
P
P
Division of Hematology and Vascular Biology Research Center, University of Texas-Houston Medical School 77030, USA.
Wu
K K
KK
D000818:Animals; D005343:Fibrinolytic Agents / Q000494:pharmacology*; D006487:Hemostasis; D006493:Heparin / Q000494:pharmacology; D006495:Heparin, Low-Molecular-Weight / Q000494:pharmacology; D006629:Hirudins / Q000031:analogs & derivatives / Q000494:pharmacology; D006801:Humans; D010446:Peptide Fragments / Q000494:pharmacology; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D018048:Receptors, Purinergic P2 / Q000187:drug effects; D011994:Recombinant Proteins / Q000494:pharmacology; D013927:Thrombosis / Q000209:etiology; D014812:Vitamin K / Q000037:antagonists & inhibitors
D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D006629:Hirudins; D010446:Peptide Fragments; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D018048:Receptors, Purinergic P2; D011994:Recombinant Proteins; D014812:Vitamin K; D006493:Heparin; C074619:bivalirudin